Trials / Completed
CompletedNCT00147758
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colesevelam hydrochloride |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-09-07
- Last updated
- 2012-01-18
Locations
47 sites across 3 countries: United States, Mexico, Peru
Source: ClinicalTrials.gov record NCT00147758. Inclusion in this directory is not an endorsement.